Small Cell Lung Cancer Market Expected to rise, 2034 | Ipsen Biopharmaceuticals, BMS, Xcovery Holding Company, EpicentRx, Amgen, expected to rise

The Small Cell Lung Cancer market growth is driven by factors like increase in the prevalence of Small Cell Lung Cancer, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Small Cell Lung Cancer market report [https://www.delveinsight.com/report-store/small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Small Cell Lung Cancer market size, share, Small Cell Lung Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Small Cell Lung Cancer market size growth forward.

Some of the key highlights from the Small Cell Lung Cancer Market Insights Report:

*
As per DelveInsight analysis, the Small Cell Lung Cancer market is anticipated to witness growth at a considerable CAGR

*
Several key pharmaceutical companies, including Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, Amgen, and others, are developing novel products to improve the Small Cell Lung Cancer treatment outlook.

*
In December 2024, Xcovery Holdings, Inc. announced that the U.S. Food and Drug Administration has approved ensartinib (Ensacove) for treating patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval represents a significant step forward in offering a new first-line treatment option for patients with ALK-positive NSCLC.

*
In September 2024, AbbVie filed a biologics license application (BLA) with the FDA, requesting accelerated approval for telisotuzumab vedotin (Teliso-V) to treat patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) that shows c-Met protein overexpression.

*
According to DelveInsight, the Small Cell Lung Cancer (SCLC) market is expected to experience significant growth between 2024 and 2034, driven by the introduction of new therapies and a rise in the number of cases. Lung cancer affects over 200,000 people annually in the United States and an estimated 2.3 million globally. Small Cell Lung Cancer accounts for 10% to 15% of lung cancer cases. The 5-year relative survival rate for individuals with SCLC in the U.S. is 8% for women and 6% for men.

*
Treatments for SCLC include IMFINZI (durvalumab) for extensive-stage SCLC and ZEPZELCA (lurbinectedin) for metastatic cases. Approximately 25% of individuals with limited-stage SCLC can be cured with timely chemotherapy and radiation therapy. The long-standing treatment approach involves platinum etoposide, with topotecan serving as a second-line option for those who respond well to platinum-based therapies. Although topotecan has a response rate of around 20%, its survival benefit is limited compared to the best supportive care.

*
The number and effectiveness of SCLC treatments remain far behind those for non-Small Cell Lung Cancer, which has seen significant advancements in targetable therapies and better responses to immunotherapy. Recently, immunotherapy has shown promise for SCLC, but challenges regarding toxicity and efficacy remain, and additional treatment options are needed to address the disease's various subtypes. Key companies such as Ipsen Biopharmaceuticals (Onivyde), Bristol-Myers Squibb (BMS-986012), Xcovery Holding Company (Vorolanib), EpicentRx (RRx-001), and Amgen (AMG 757) are advancing their lead candidates through various stages of clinical development.

*
In 2023, it is estimated that there will be approximately 238,340 new cases of lung cancer in the United States, with 117,550 cases in men and 120,790 cases in women. The statistics typically include both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). SCLC accounts for about 10% to 15% of all lung cancers, while NSCLC makes up approximately 80% to 85%.

*
In the U.S., Small Cell Lung Cancer is slightly more common in women (14%) than in men (13%). The risk of developing lung cancer increases with age, and both men and women are most likely to be diagnosed with Small Cell Lung Cancer between the ages of 75 and 79.

*
In the UK, around 15% to 20% of all lung cancer diagnoses are Small Cell Lung Cancer, which is primarily caused by smoking. This type of cancer tends to spread early in its progression.

Strategise your business goals by understanding market dynamics @ Small Cell Lung Cancer Market Landscape [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Small Cell Lung Cancer Overview

Small Cell Lung Cancer (SCLC) is a highly aggressive form of lung cancer characterized by the rapid and uncontrolled growth of cells within the lungs, often leading to tumor development and metastasis to other parts of the body. Smoking is the primary risk factor, with almost all cases occurring in individuals who currently smoke or have a history of smoking. Early stages of the disease typically present no noticeable symptoms, and when symptoms do appear, they can vary widely among patients.

To diagnose lung cancer, doctors usually recommend imaging tests like CT, PET, or MRI scans to identify any lung abnormalities. A mucus sample may also be analyzed for cancer cells. If cancer is suspected, a biopsy - involving either a needle insertion or a small surgical procedure - is performed to collect lung tissue for examination. Bronchoscopy is another common technique used to view the lungs directly and obtain tissue samples.

Do you know the treatment paradigms for different countries? Download our Small Cell Lung Cancer Market Sample Report [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Small Cell Lung Cancer Epidemiology Segmentation

DelveInsight's Small Cell Lung Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Small Cell Lung Cancer historical patient pools and forecasted Small Cell Lung Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Small Cell Lung Cancer Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Small Cell Lung Cancer Prevalence

*
Age-Specific Small Cell Lung Cancer Prevalence

*
Gender-Specific Small Cell Lung Cancer Prevalence

*
Diagnosed and Treatable Cases of Small Cell Lung Cancer

Visit for more @ Small Cell Lung Cancer Epidemiological Insights [https://www.delveinsight.com/report-store/small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Small Cell Lung Cancer Treatment Market

Over the past 30 years, progress in improving survival rates for Small Cell Lung Cancer (SCLC) patients has been minimal, largely due to the cancer's aggressive growth, early metastasis, and resistance to chemotherapy. Treatment decisions are based on the cancer stage, patient health, and personal preferences, and may involve surgery, chemotherapy, radiation, or immunotherapy. Standard chemotherapy typically includes Etoposide or Irinotecan with a platinum-based drug like Cisplatin or Carboplatin. Limited-stage SCLC is treated with combined chemotherapy and radiation, while extensive-stage disease often involves chemotherapy, sometimes paired with immunotherapy.

Recent advancements have introduced immune checkpoint inhibitors like nivolumab, pembrolizumab, atezolizumab, and durvalumab for first-line therapy. Lurbinectedin is now approved for second-line treatment, and trilaciclib helps prevent chemotherapy-induced myelosuppression. However, in 2021, approvals for nivolumab and pembrolizumab in later-stage treatment were withdrawn, though they remain in use alongside other therapies.

Research is ongoing to develop new treatments, with hopes that biomarker-driven approaches will significantly improve outcomes, much like in non-Small Cell Lung Cancer (NSCLC). Companies like Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, and Amgen are actively advancing new therapies through clinical trials.

Small Cell Lung Cancer Marketed Drugs

*
ZEPZELCA (lurbinectedin): PharmaMar and Jazz Pharmaceuticals

*
IMFINZI (durvalumab): AstraZeneca

Small Cell Lung Cancer Emerging Drugs

*
RRx-001: EpicentRx

Small Cell Lung Cancer Key Companies

*
Bristol-Myers Squibb

*
Merck

*
AstraZeneca

*
PharmaMar

*
EpicentRx

*
And others

For more information, visit Small Cell Lung Cancer Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Small Cell Lung Cancer Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Small Cell Lung Cancer, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Small Cell Lung Cancer epidemiology in the 7MM

*
Small Cell Lung Cancer marketed and emerging therapies

*
Small Cell Lung Cancer companies

*
Small Cell Lung Cancer market drivers and barriers

Table of Contents:

1 Small Cell Lung Cancer Market Key Comprehensive Insights

2 Small Cell Lung Cancer Market Report Introduction

3 Competitive Intelligence Analysis for Small Cell Lung Cancer

4 Small Cell Lung Cancer Market Analysis Overview at a Glance

5 Executive Summary of Small Cell Lung Cancer

6 Small Cell Lung Cancer Epidemiology and Market Methodology

7 Small Cell Lung Cancer Epidemiology and Patient Population

8 Small Cell Lung Cancer Patient Journey

9 Small Cell Lung Cancer Treatment Algorithm, Small Cell Lung Cancer Current Treatment, and Medical Practices

10 Key Endpoints in Small Cell Lung Cancer Clinical Trials

11 Small Cell Lung Cancer Marketed Therapies

12 Small Cell Lung Cancer Emerging Therapies

13 Small Cell Lung Cancer: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Small Cell Lung Cancer

16 Small Cell Lung Cancer Market Key Opinion Leaders Reviews

18 Small Cell Lung Cancer Market Drivers

19 Small Cell Lung Cancer Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Small Cell Lung Cancer Epidemiology 2034

DelveInsight's "Small Cell Lung Cancer - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Small Cell Lung Cancer Pipeline 2024

"Small Cell Lung Cancer Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Small Cell Lung Cancer market. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Small Cell Lung Cancer treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=small-cell-lung-cancer-market-expected-to-rise-2034-ipsen-biopharmaceuticals-bms-xcovery-holding-company-epicentrx-amgen-expected-to-rise]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.